NovoCure Ltd (NVCR)

Name: NovoCure Ltd (NVCR) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001645113 · Nasdaq · Surgical & Medical Instruments & Apparatus

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, NovoCure Ltd reported revenue of $655.35M. Revenue grew 8.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $699.19M.

Key ratios (year ended 2025-12-31)

74.5%

Gross margin

-23.5%

Operating margin

-20.8%

Net margin

-40.0%

Return on year-end equity

8.3%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-01

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$699.19M	$655.35M	$605.22M	$509.34M	$537.84M	$535.03M	$494.37M	$351.32M	$248.07M	$177.03M	$82.89M
Cost of Revenue	$166.92M	$166.88M	$137.18M	$128.28M	$114.87M	$114.88M	$106.50M	$88.61M	$80.05M	$55.61M	$39.87M
Gross Profit	$532.27M	$488.47M	$468.04M	$381.06M	$422.97M	$420.15M	$387.87M	$262.71M	$168.02M	$121.42M	$36.61M
R&D Expense	$224.72M	$224.54M	$209.65M	$223.06M	$206.09M	$201.30M	$132.01M	$79.00M	$50.57M	$38.10M	$41.47M
Operating Income	-$154.40M	-$153.80M	-$170.50M	-$232.87M	-$89.52M	-$44.33M	$30.40M	-$914.0K	-$33.67M	-$39.33M	-$115.32M
Depreciation & Amortization	$16.31M	$14.65M	$11.23M	$10.97M	$10.62M	$10.25M	$9.15M	$8.46M	$9.01M	$7.68M	$5.65M
EBITDA	-$138.08M	-$139.15M	-$159.26M	-$221.90M	-$78.90M	-$34.08M	$39.55M	$7.55M	-$24.67M	-$31.65M	-$109.67M
Net Income	-$148.56M	-$136.23M	-$168.63M	-$207.04M	-$92.53M	-$58.35M	$19.81M	-$7.23M	-$63.56M	-$61.66M	-$131.84M
EPS (Diluted)	n/a	-$1.22	-$1.56	-$1.95	-$0.88	-$0.56	$0.18	-$0.07	-$0.69	n/a	n/a
Total Assets	$795.19M	$804.33M	$1.24B	$1.15B	$1.19B	$1.14B	$1.05B	$479.45M	$339.79M	$265.30M	$282.08M
Total Liabilities	$457.10M	$463.86M	$880.61M	$783.63M	$750.48M	$729.00M	$575.46M	$261.66M	$227.53M	$151.73M	$139.74M
Long-Term Debt	n/a	n/a	n/a	$568.82M	$565.51M	$562.22M	$429.90M	$149.42M	n/a	n/a	n/a
Shareholders' Equity	$338.09M	$340.47M	$360.18M	$362.50M	$441.17M	$410.49M	$476.53M	$217.79M	$112.26M	$113.56M	$142.34M
Cash & Equivalents	$93.70M	$93.55M	$163.77M	$240.82M	$115.33M	$208.80M	$234.67M	$177.32M	$140.62M	$78.59M	$99.78M
Operating Cash Flow	-$2.81M	-$49.03M	-$26.37M	-$73.34M	$30.79M	$82.76M	$99.15M	$26.62M	-$1.86M	-$33.13M	-$107.59M
Capital Expenditures	$22.62M	$26.65M	$42.85M	$27.09M	$21.36M	$24.17M	$14.97M	$10.48M	$6.71M	$7.37M	$5.67M
Free Cash Flow	-$25.43M	-$75.68M	-$69.22M	-$100.43M	$9.43M	$58.59M	$84.18M	$16.14M	-$8.58M	-$40.50M	-$113.27M
Dividends Paid	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$0	$0
Shares Outstanding	116.44M	112.49M	108.52M	107.08M	105.05M	103.97M	102.33M	99.53M	93.25M	89.48M	87.07M
Weighted Average Diluted Shares	n/a	111.47M	107.83M	106.39M	104.66M	103.43M	108.88M	97.24M	91.83M	n/a	n/a
EPS (Basic)	n/a	-$1.22	-$1.56	-$1.95	-$0.88	-$0.56	$0.20	-$0.07	-$0.69	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView